Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Elanco Animal Health Incorporated (ELAN) , which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, could be a great candidate to consider. This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 27 ...

SAN FRANCISCO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Elanco Animal Health (NYSE: ELAN) is facing a securities class action lawsuit alleging the company misled investors about the safety and regulatory path of its new dermatology drug, Zenrelia. Hagens Berman urges Elanco investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 – June 26, 2024 Lead Plaintiff Deadline: Dec. 6, 2024 Visit: www.hbsslaw.com/investor-fraud/elan Contact the Firm Now: ELAN@hbsslaw.com 844-916-0895 ...

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=108706&fro ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=108477 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Elanco between November 7, 2023 and June 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2024 (GLOBE NEW ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-healt ...

文章核心观点 - 公司正在开发两款新药物Zenrelia和Credelio Quattro,预计在2024年获得FDA批准并上市 [1][2] - 但公司在2024年6月27日发布公告称,Zenrelia的美国标签将包含安全性方面的警示,预计会影响产品的市场接受度和销量 [2] - 同时公司也推迟了Zenrelia和Credelio Quattro的FDA批准和上市时间表 [2] - 这些负面消息导致公司股价在2024年6月27日下跌20.53% [2] 根据相关目录分别进行总结 公司概况 - 公司是一家从事宠物和农场动物药品研发、生产和销售的动物健康公司 [1] 新药研发进展 - 公司正在开发一种名为Zenrelia的每日一次口服JAK抑制剂,用于犬皮肤病治疗 [1] - 公司还在开发一种名为Credelio Quattro的广谱驱虫产品,用于犬 [1] - 公司原计划在2024年第三季度获得Zenrelia的FDA批准,第四季度上市 [2] - 公司原计划在2024年第四季度获得Credelio Quattro的FDA批准 [2] 新药审批进展 - 公司表示Zenrelia的美国标签将包含安全性方面的警示,这可能会影响产品的市场接受度和销量 [2] - 公司推迟了Zenrelia和Credelio Quattro的FDA批准和上市时间表 [2]

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=107864&fro ...